AbbVie (ABBV) News Today

AbbVie Inc. (ABBV) — shares are down after a mixed news flow. Positive catalysts (strong drug wins, pipeline progress and M&A) support upside, but near-term selling and analyst EPS cuts are weighing on the stock following a large run-up earlier this year.

• Positive Sentiment: Key trial result: AbbVie's Rinvoq outperformed Humira in a major arthritis trial — a clinical win that supports continued commercial momentum for its immunology franchise. Article Title
• Positive Sentiment: Migraine pipeline progress: Positive Phase 3 update for atogepant signals growth beyond core immunology drugs and strengthens long-term revenue diversification. Article Title
• Positive Sentiment: M&A: AbbVie completed the acquisition of Gilgamesh Pharma (bretilsilocin), expanding its CNS/migraine portfolio and pipeline breadth. Article Title
• Positive Sentiment: Analyst support: A Cerity Partners commentator highlighted AbbVie’s attractive valuation and dividend yield, which can attract income-focused buyers. Article Title
• Neutral Sentiment: Momentum note: Zacks and other outlets highlight that ABBV is up >30% in six months driven by Skyrizi/Rinvoq and oncology gains — that explains some recent profit-taking. Article Title
• Neutral Sentiment: Investor interest: Zacks and MarketBeat pieces note ABBV as a trending/long-term dividend pick, underscoring buy-and-hold narratives even as volatility continues. Article Title
• Negative Sentiment: Estimate cuts: Zacks Research trimmed Q1 2026 EPS forecasts and flagged a negative near-term outlook, which likely contributed to downward pressure on the share price. Article Title

Takeaway for investors: the stock’s pullback reflects short-term profit-taking and an analyst EPS reduction despite tangible product- and pipeline-driven positives (Rinvoq/Skyrizi momentum, migraine program, M&A). If you hold ABBV, weigh near-term estimate risk against durable cash flow, dividend strength and recent clinical/commercial catalysts.